# Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

> **NCT00016549** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT00016549
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05-13
- **Primary completion:** 2007-01-29
- **Final completion:** 2007-01-29
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016549, "Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00016549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*